芪参益气滴丸联合新型口服抗凝药干预高危非瓣膜性房颤患者的临床观察  

Clinical Observation of Qishen Yiqi Dropping Pills Combined with new Oral Anticoagulants in the Intervention of Patients with High-risk Non-valvular Atrial Fibrillation

作　　者：王霄 邵正斌[2] 魏青 WANG Xiao;SHAO Zhengbin;WEI Qing(Anhui University of Chinese Medicine,Anhui Hefei 230012,China;The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine,Anhui Hefei 230031,China)

机构地区：[1]安徽中医药大学,安徽合肥230012 [2]安徽中医药大学第一附属医院,安徽合肥230031

出　　处：《中医药临床杂志》2024年第2期324-328,共5页Clinical Journal of Traditional Chinese Medicine

摘　　要：目的:观察芪参益气滴丸联合低剂量利伐沙班治疗高危非瓣膜性房颤(Non-Valvular Atrial Fibrillation,NVAF)患者的临床疗效及安全性。方法:采用随机数字表法将符合标准的60例高危NVAF患者随机分为对照组和治疗组,每组各30例;对照组予10mg利伐沙班qd,治疗组在对照组基础上联合芪参益气滴丸1袋,3次/d;观察2组患者治疗前后血小板、D-二聚体、活化部分凝血酶原时间(APTT)、血浆凝血酶原时间(PT)、生活质量评分、中医症候积分、EHRA房颤症状评分、房颤负荷以及栓塞事件、出血事件的发生率。结果:治疗后2组患者血小板、D-二聚体、中医症候积分、房颤负荷、EHRA房颤症状评分均下降(P<0.05),生活质量评分上升(P<0.05),差异具有统计学意义,且治疗组上述指标改善程度较对照组更优(P<0.05);APTT、PT均较治疗前延长(P<0.05),差异有统计学意义;但治疗组与对照组相比PT、APTT延长并不明显,无统计学意义(P>0.05);治疗后2组患者栓塞事件、出血事件比较未见明显差异(P>0.05),无统计学意义。结论:芪参益气滴丸与低剂量利伐沙班联合治疗高危NVAF患者具有确切的临床疗效,能够有效地预防卒中事件发生、提高患者生活质量水平,且安全性较高。Objective:To observe the clinical efficacy and safety of Qishen Yiqi Dropping Pills combined with lowdose rivaroxaban in the treatment of high-risk patients with non-valvular atrial fibrillation(NVAF).Methods:Using the random number table method,60 patients with high-risk non-valvular atrial fibrillation who met the criteria were randomly divided into a control group and a treatment group,with 30 cases in each group.The control group was given 10 mg rivaroxaban qd,and the treatment group was given 10 mg rivaroxaban qd.Basically,combined with 1 bag of Qishen Yiqi Dropping Pills,tid;observed the platelet(PLT),D-dimer(D-D),activated partial prothrombin time(APTT),plasma prothrombin time(PT),quality of life score,TCM symptom score,EHRA atrial fibrillation symptom score,atrial fibrillation burden,and the incidence of embolic events and bleeding events.Results:After treatment,the PLT,D-D,TCM symptom scores,atrial fibrillation burden,and EHRA atrial fibrillation symptom scores of the two groups of patients all decreased(P<0.05),and the quality of life scores increased(P<0.05).The difference was statistically significant,and after treatment The improvement degree of the above indicators in the treatment group was better than that in the control group(P<0.05);APTT and PT were both longer than before treatment(P<0.05),and the difference was statistically significant;but compared with the control group,the PT and APTT were not longer in the treatment group.Obviously,there was no statistical significance(P>0.05);there was no significant difference in embolic events and bleeding events between the two groups after treatment(P>0.05),which was not statistically significant.Conclusion:Qishen Yiqi Dropping Pills combined with low-dose rivaroxaban has definite clinical efficacy in the treatment of highrisk non-valvular atrial fibrillation patients,can effectively prevent stroke events,improve patients’quality of life,and is highly safe.

关 键 词：芪参益气滴丸 低剂量利伐沙班 高危 非瓣膜性房颤 

分 类 号：R541.75[医药卫生—心血管疾病]